Device-therapy in chronic heart failure: Cardiac contractility modulation versus cardiac resynchronization therapy.

ESC Heart Fail

Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Published: September 2024

AI Article Synopsis

  • Cardiac implantable devices like CRT-Ds and CCMs are options for patients with heart failure and reduced left ventricular function despite medical treatment, but a direct comparison between the two has not been done before.* -
  • The study analyzed data from two registries to compare 220 CRT-D patients and 105 CCM patients, finding that before treatment, CCM patients had worse heart function; however, both groups showed similar improvements after 12 months.* -
  • Despite comparable functional improvements, CCM patients had significantly higher rates of heart failure hospitalizations (45.7% compared to 16.8% for CRT-D patients), indicating a potential downside to CCM therapy.*

Article Abstract

Aims: Cardiac implantable electrical devices such as cardiac resynchronization therapy with defibrillator (CRT-Ds) or cardiac contractility modulation (CCMs) are therapy options for patients with symptomatic heart failure (HF) and reduced left ventricular ejection fraction (LVEF) despite optimal medical treatment. As yet, a comparison between both devices has not been performed.

Methods And Results: The Mannheim Cardiac Resynchronization Therapy Registry (MARACANA) and the Mannheim Cardiac Contractility Modulation Observational Study (MAINTAINED) included all patients who received CRTs or CCMs in our medical centre between 2012 and 2021. For the present analysis, we retrospectively compared patients provided with either CRT-Ds (n = 220) or CCMs with additional defibrillators (n = 105) regarding New York Heart Association classification (NYHA), LVEF, tricuspid annular plane systolic excursion (TAPSE), QRS-width and other HF modification aspects after 12 months. Before implantation, CCM patients presented with lower LVEF (23.6 ± 6.2 vs. 26.3 ± 6.5%) and worse NYHA (3.03 ± 0.47 vs. 2.81 ± 0.48, both P < 0.05), compared with CRT-D patients. Follow-up improvements in NYHA (2.43 ± 0.67 vs. 2.28 ± 0.72), LVEF (30.5 ± 10.7 vs. 35.2 ± 10.5%) and TAPSE (17.2 ± 5.2 vs. 17.1 ± 4.8 to 18.9 ± 3.4 vs. 17.3 ± 3.6 mm, each P < 0.05) were comparable. The intrinsic QRS-width was stable with CCM (109.1 ± 18 vs. 111.7 ± 19.7 ms, P > 0.05), while the paced QRS-width with CRT-D after 12 months was lower than intrinsic values at baseline (157.5 ± 16.5 vs. 139.2 ± 16 ms, P < 0.05). HF hospitalizations occurred more often for CCM than CRT-D patients (45.7 vs. 16.8%/patient years, odds ratio 4.2, P < 0.001).

Conclusions: Chronic heart failure patients could experience comparable 12-month improvements in functional status and ventricular reverse remodelling, with appropriately implanted CCMs and CRT-Ds. Differences in HF hospitalization rates may be due to the more advanced HF of CCM patients at implantation.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ehf2.15067DOI Listing

Publication Analysis

Top Keywords

cardiac contractility
12
contractility modulation
12
cardiac resynchronization
12
resynchronization therapy
12
heart failure
8
mannheim cardiac
8
cardiac
7
device-therapy chronic
4
chronic heart
4
failure cardiac
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!